Oral Answers to Questions

Martyn Day Excerpts

Tuesday 23rd October 2018 Commons Chamber

[Alan Brown (Kilmarnock and Loudoun) (SNP)]

12. What assessment he has made of the potential effect on access to new medicines of the UK leaving the EU.

[Martyn Day (Linlithgow and East Falkirk) (SNP)]

20. What assessment he has made of the potential effect on access to new medicines of the UK leaving the EU.

--- Later in debate ---

[Matt Hancock]

Not only does the UK bring a huge amount to the table in terms of research, but we fully intend to make sure that we have a robust and seamless system in place. A consultation is out at the moment and we will respond to it very shortly.

[Martyn Day]

The Government have stated that the new EU clinical trials regulations will not be in place before March, but have committed to aligning with it where possible. What progress has been made regarding data sharing to ensure that clinical trials continue and pharmaceutical and research firms do not leave the UK after Brexit?

[Matt Hancock]

As part of the EU deal we are negotiating, the relationship with the EMA will be extremely close, so I am sure that that will be a part of our agreement.